Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820178 | 0.90 | FGFR1 (0.81) | FGFR1SRCRAB9ANPC1HPGD | |
| SCHEMBL7975748 | 0.89 | FGFR1 (0.81) | FGFR1SRCRAB9AHPGDMAPT | |
| Hydrochloric Acid SCHEMBL7986510 | 0.88 | FGFR1 (0.79) | FGFR1SRCRAB9AHPGDMAPT | |
| SCHEMBL4502855 | 0.88 | FGFR1 (0.79) | FGFR1RAB9AHPGDMAPTGSK3B | |
| SCHEMBL23675157 | 0.87 | FGFR1 (0.77) | FGFR1HPGD | |
| SCHEMBL2340072 | 0.87 | FGFR1 (0.77) | FGFR1RAB9AHPGDSMN1; SMN2MAPT | |
| SCHEMBL14065339 | 0.87 | FGFR1 (0.77) | FGFR1RAB9ANPC1HPGDMAPT | |
| SCHEMBL23675303 | 0.87 | FGFR1 (0.77) | FGFR1RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL144945 | 0.87 | FGFR1 (0.77) | FGFR1RAB9ANPC1HPGDMAPT | |
| SCHEMBL6875300 | 0.86 | FGFR1 (0.76) | FGFR1RAB9ANPC1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193224-B2 | Medicinal composition for prevention or treatment of parasitic protozoan infection | FUJIFILM CORPORATION (JP) | 2012-06-05 | — | — | US | disclosed |
| EP-1818334-B1 | ANTI-TRYPANOSOMIASIS AGENT | IHARA MASATAKA (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7795285-B2 | Anti-trypanosomiasis agent | FUJIFILM CORPORATION (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20100113789-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION | Ihara, Masataka (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20090076067-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AZARHODACYANINE COMPOUND AS ACTIVE INGREDIENT | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1894920-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AZARHODACYANINE COMPOUND AS ACTIVE INGREDIENT | Japan Science and Technology Agency (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20080045574-A1 | thiazolidin-4-one derivatives used as antiprotozoa agents, or for the treatment of trypanosomiasis | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1818334-A1 | ANTI-TRYPANOSOMIASIS AGENT | Japan Science and Technology Agency (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1800682-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION | Japan Science and Technology Agency (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-6218388-B1 | THERAPY OF PROTEIN TYROSINE KINASE MEDIATED CANCER, ATHEROSCLEROSIS, RESTENOSIS, AND PSORIASIS BY ADMINISTERING BENZIMIDAZOLE DERIVATIVE | WARNER-LAMBERT COMPANY | 2001-04-17 | — | — | US | disclosed |
| US-5990146-A | TREATING PROTEIN TYROSINE KINASE MEDIATED CANCER; ANTICARCINOGENIC AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS; ANTIPROLIFERATIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076067-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AZARHODACYANINE COMPOUND AS ACTIVE INGREDIENT | CTSA, GPAA1, CD47 | FGFR1 4728/4885SRC 2384/4885RAB9A 1006/4885 |
| US-20080045574-A1 | thiazolidin-4-one derivatives used as antiprotozoa agents, or for the treatment of trypanosomiasis | TXN2, SQOR, TXNRD2 | FGFR1 4572/4885SRC 4150/4885RAB9A 2331/4885 |
| US-20100113789-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION | MRM1, NR1I3, RORA | FGFR1 4373/4885SRC 1223/4885RAB9A 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.